Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tdap Vaccination in Rheumatoid Arthritis
NCT01301703Phase 4Unknown
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- Mar 2011
- Primary completion
- Dec 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of acellular pertussis vaccine in pertussis, Tetanus and diphtheria, sponsored by Tel Aviv Sourasky Medical Center. Primary endpoint: Immunogenicity of Tdap. Status: unknown.
02
Drugs
acellular pertussis vaccine
03
Conditions
pertussisTetanusdiphtheria
Beyond the preview
Go deeper on NCT01301703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01301703.